Investors who incurred significant losses in POMDoctor Ltd. (NASDAQ: POM) are encouraged to contact Robbins LLP regarding a recently filed class action lawsuit. The lawsuit covers all individuals who purchased or acquired POMDoctor securities between October 9, 2025, and December 11, 2025. POMDoctor, which claims to be “a leading online medical services platform for chronic diseases in China,” is facing serious allegations of a fraudulent scheme.
According to the complaint, POMDoctor’s share price experienced a remarkable increase from its initial public offering (IPO) price of $4.00 to a peak of $6.09 in the weeks leading up to the IPO on December 10, 2025. This surge occurred without any substantial news or developments from the company, raising suspicions about the legitimacy of the price rise.
Investigations have revealed that POMDoctor may have engaged in a “pump-and-dump” scheme, utilizing social media to mislead investors. Allegedly, impersonators posing as legitimate financial advisors promoted POMDoctor in various online forums, chat groups, and social media platforms, making sensational claims that lacked any basis in fact. This tactic aimed to create a buying frenzy among retail investors.
On the day of the IPO, POMDoctor’s share price plummeted by approximately 91%, dropping to $0.50. Since then, the stock price has continued to decline, now hovering around $0.40. The lawsuit claims that during the class period, the defendants failed to disclose critical information to investors, including that POMDoctor was subject to a promotional scheme involving misinformation and impersonated financial professionals. Furthermore, it alleges that insiders may have used offshore accounts to facilitate the selling of shares during the artificially inflated price period.
As the situation unfolds, shareholders of POMDoctor Ltd. have options available to them. Those interested in serving as lead plaintiffs in the class action must submit their applications to the court by April 7, 2026. The lead plaintiff represents other class members in the litigation process. Importantly, individuals do not need to actively participate in the case to be eligible for any recovery; they may choose to remain absent class members.
For further details or to participate in the class action, shareholders can submit a form, contact attorney Aaron Dumas, Jr., or call Robbins LLP at (800) 350-6003. All representation is provided on a contingency fee basis, meaning shareholders incur no fees or expenses unless the case is successful.
Robbins LLP has established a strong reputation in shareholder rights litigation, having dedicated itself to helping investors recover losses and improve corporate governance since 2002. To stay informed about this class action against POMDoctor Ltd. or to receive alerts concerning corporate misconduct, individuals can sign up for Stock Watch.
Attorney advertising is noted, and past results do not guarantee similar outcomes in future cases.
